NervGen Pharma readies trials for biologic treatment of spinal cord injury, multiple sclerosis

Alan Condon -   Print  |

NervGen Pharma is planning its clinical development strategy for its compound, NVG-291, in spinal cord injury and multiple sclerosis patients.

Four things to know:

1. NVG-291 is a linear peptide comprised of common amino acids.

2. Its Phase 1 safety and pharmacokinetic study in healthy subjects will begin in the first quarter of 2020.

3. The expansion of its Phase 1 trial on spinal cord injury patients will begin in the second half of 2020.

4. A Phase 2 multiple sclerosis trial is set for the first quarter of 2021.

More articles on biologics:
'A dream come true': Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker's spine division stands to gain from 5 acquisitions

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers